Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

739 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. Among authors: van cutsem e. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases.
Plummer R, Greystoke A, Naylor G, Sarker D, Anam ANMK, Prenen H, Teuwen LA, Van Cutsem E, Dekervel J, Haugk B, Ness T, Bhoi S, Jensen M, Morris T, Baumann P, Sjögren N, Tunblad K, Wallberg H, Öberg F, Evans TRJ. Plummer R, et al. Among authors: van cutsem e. J Hepatocell Carcinoma. 2024 Oct 24;11:2033-2047. doi: 10.2147/JHC.S481410. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39469286 Free PMC article. Clinical Trial.
Efficacy and safety of the anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in patients with advanced/metastatic pancreatic cancer.
Van Cutsem E, Collignon J, Eefsen RL, Ochsenreither S, Zvirbule Z, Ivanauskas A, Arnold D, Baltruskeviciene E, Pfeiffer P, Yachnin J, Magnusson S, Rydberg Millrud C, Sanfridson A, Losic N, Garcia-Ribas I, Tersago D, Awada A. Van Cutsem E, et al. Clin Cancer Res. 2024 Oct 10. doi: 10.1158/1078-0432.CCR-24-0645. Online ahead of print. Clin Cancer Res. 2024. PMID: 39385434
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer.
André T, Van Cutsem E, Taieb J, Fakih M, Prager GW, Ciardiello F, Falcone A, Saunders M, Amellal N, Roby L, Tabernero J, Pfeiffer P. André T, et al. Among authors: van cutsem e. Curr Treat Options Oncol. 2024 Oct;25(10):1312-1322. doi: 10.1007/s11864-024-01261-w. Epub 2024 Sep 26. Curr Treat Options Oncol. 2024. PMID: 39325367 Free PMC article. Review.
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH. Shitara K, et al. Among authors: van cutsem e. N Engl J Med. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16. N Engl J Med. 2024. PMID: 39282934 No abstract available.
Pembrolizumab in HER2-Positive Gastric Cancer.
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, Yañez P, Wyrwicz LS, Shen L, Ostapenko Y, Bilici M, Chung HC, Shitara K, Qin S, Van Cutsem E, Tabernero J, Luo S, Mahave M, Tang Y, Lowery M, Monteiro MMF, Xu L, Shih CS, Sharan KP, Bhagia P, Rha SY. Janjigian YY, et al. Among authors: van cutsem e. N Engl J Med. 2024 Oct 10;391(14):1360-1362. doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14. N Engl J Med. 2024. PMID: 39282917 Clinical Trial. No abstract available.
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.
Lordick F, Van Cutsem E, Shitara K, Xu RH, Ajani JA, Shah MA, Oh M, Ganguli A, Chang L, Rhoten S, Bhattacharya P, Matsangou M, Park JW, Pophale R, Ranganath R, Kang YK. Lordick F, et al. Among authors: van cutsem e. ESMO Open. 2024 Aug;9(8):103663. doi: 10.1016/j.esmoop.2024.103663. Epub 2024 Aug 14. ESMO Open. 2024. PMID: 39146670 Free PMC article. Clinical Trial.
739 results